Home
>
US Stocks
>
Procept Biorobotics

Procept Biorobotics (PRCT)

$34.02

+0.1

(+0.29%)▲

Market is closed - opens 7 PM, 12 Jun 2023

Insights on Procept Biorobotics

  • Increasing Revenue

    Revenue is up for the last 11 quarters, 2.10M → 24.40M (in $), with an average increase of 19.9% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 5 quarters, -17.18M → -28.48M (in $), with an average decrease of 13.8% per quarter

  • Vs BSX

    In the last 1 year, Boston Scientific Corp. has given 37.7% return, outperforming this stock by 54.9%

Performance

  • $33.50
    $34.31
    $34.02
    downward going graph

    1.53%

    Downside

    Day's Volatility :2.36%

    Upside

    0.85%

    downward going graph
  • $25.29
    $52.40
    $34.02
    downward going graph

    25.66%

    Downside

    52 Weeks Volatility :51.74%

    Upside

    35.08%

    downward going graph

Returns

PeriodProcept BioroboticsSector (Health Care)Index (Russel 2000)
3 Months
10.22%
5.1%
-0.2%
6 Months
-21.19%
-5.5%
-1.5%
1 Year
-17.17%
3.9%
-1.7%
3 Years
-19.27%
27.0%
20.6%

Highlights

Market Capitalization
1.5B
Book Value
$3.85
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
-2.27
Wall Street Target Price
49.86
Profit Margin
-115.53%
Operating Margin TTM
-109.59%
Return On Assets TTM
-19.29%
Return On Equity TTM
-46.24%
Revenue TTM
85.2M
Revenue Per Share TTM
1.91
Quarterly Revenue Growth YOY
71.89999999999999%
Gross Profit TTM
37.1M
EBITDA
-90.5M
Diluted Eps TTM
-2.27
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-2.2
EPS Estimate Next Year
-1.75
EPS Estimate Current Quarter
-0.58
EPS Estimate Next Quarter
-0.58

Analyst Recommendation

Buy
    85%Buy
    14%Hold
    0
    0%Sell
Based on 14 Wall street analysts offering stock ratings for Procept Biorobotics(by analysts ranked 0 to 5 stars)
Based on 14 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
12
12
12
Hold
2
2
2
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 46.56%

Current $34.02
Target $49.86

Company Financials

FY19Y/Y Change
Revenue
6.2M
-
Net Income
-42.0M
-
Net Profit Margin
-680.42%
-
FY20Y/Y Change
Revenue
7.7M
↑ 25.09%
Net Income
-53.0M
↑ 26.31%
Net Profit Margin
-687.04%
↓ 6.62%
FY21Y/Y Change
Revenue
34.5M
↑ 346.72%
Net Income
-59.9M
↑ 12.89%
Net Profit Margin
-173.62%
↑ 513.42%
FY22Y/Y Change
Revenue
75.0M
↑ 117.6%
Net Income
-87.2M
↑ 45.61%
Net Profit Margin
-116.18%
↑ 57.44%
Q4 FY21Q/Q Change
Revenue
12.9M
↑ 49.09%
Net Income
-33.7M
↑ 139.25%
Net Profit Margin
-261.1%
↓ 98.4%
Q1 FY22Q/Q Change
Revenue
14.2M
↑ 9.86%
Net Income
-17.2M
↓ 49.07%
Net Profit Margin
-121.05%
↑ 140.05%
Q2 FY22Q/Q Change
Revenue
16.7M
↑ 17.57%
Net Income
-19.2M
↑ 11.63%
Net Profit Margin
-114.94%
↑ 6.11%
Q3 FY22Q/Q Change
Revenue
20.3M
↑ 21.92%
Net Income
-22.6M
↑ 17.87%
Net Profit Margin
-111.13%
↑ 3.81%
Q4 FY22Q/Q Change
Revenue
23.8M
↑ 16.85%
Net Income
-28.2M
↑ 24.58%
Net Profit Margin
-118.48%
↓ 7.35%
Q1 FY23Q/Q Change
Revenue
24.4M
↑ 2.64%
Net Income
-28.5M
↑ 1.11%
Net Profit Margin
-116.72%
↑ 1.76%
FY19Y/Y Change
Total Assets
62.0M
-
Total Liabilities
205.8M
-
FY20Y/Y Change
Total Assets
126.0M
↑ 103.2%
Total Liabilities
308.9M
↑ 50.06%
FY21Y/Y Change
Total Assets
337.0M
↑ 167.54%
Total Liabilities
69.9M
↓ 77.36%
FY22Y/Y Change
Total Assets
309.3M
↓ 8.22%
Total Liabilities
112.3M
↑ 60.52%
Q4 FY21Q/Q Change
Total Assets
337.0M
↓ 4.11%
Total Liabilities
69.9M
↑ 2.61%
Q1 FY22Q/Q Change
Total Assets
320.9M
↓ 4.78%
Total Liabilities
68.2M
↓ 2.53%
Q2 FY22Q/Q Change
Total Assets
310.9M
↓ 3.11%
Total Liabilities
71.7M
↑ 5.25%
Q3 FY22Q/Q Change
Total Assets
324.0M
↑ 4.22%
Total Liabilities
103.3M
↑ 43.96%
Q4 FY22Q/Q Change
Total Assets
309.3M
↓ 4.54%
Total Liabilities
112.3M
↑ 8.7%
Q1 FY23Q/Q Change
Total Assets
284.5M
↓ 8.04%
Total Liabilities
111.3M
↓ 0.82%
FY19Y/Y Change
Operating Cash Flow
-43.8M
-
Investing Cash Flow
43.2M
-
Financing Cash Flow
26.5M
-
FY20Y/Y Change
Operating Cash Flow
-48.3M
↑ 10.33%
Investing Cash Flow
-233.0K
↓ 100.54%
Financing Cash Flow
106.8M
↑ 302.5%
FY21Y/Y Change
Operating Cash Flow
-57.3M
↑ 18.6%
Investing Cash Flow
-592.0K
↑ 154.08%
Financing Cash Flow
262.1M
↑ 145.49%
Q4 FY21Q/Q Change
Operating Cash Flow
-33.6M
↑ 163.78%
Investing Cash Flow
-332.0K
↑ 199.1%
Financing Cash Flow
8.8M
↓ 94.97%
Q1 FY22Q/Q Change
Operating Cash Flow
-18.2M
↓ 45.8%
Investing Cash Flow
-55.0K
↓ 83.43%
Financing Cash Flow
1.3M
↓ 85.26%
Q2 FY22Q/Q Change
Operating Cash Flow
-17.1M
↓ 6.06%
Investing Cash Flow
-218.0K
↑ 296.36%
Financing Cash Flow
2.9M
↑ 121.69%
Q3 FY22Q/Q Change
Operating Cash Flow
-19.9M
↑ 15.91%
Investing Cash Flow
-1.5M
↑ 594.5%
Financing Cash Flow
777.0K
↓ 72.85%
Q1 FY23Q/Q Change
Operating Cash Flow
-35.9M
↑ 42.72%
Investing Cash Flow
-5.3M
-
Financing Cash Flow
380.0K
↓ 128.83%

Technicals Summary

Sell

Neutral

Buy

Procept Biorobotics is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Procept Biorobotics
Procept Biorobotics
14.79%
-21.19%
-17.17%
-19.27%
-19.12%
Stryker Corporation
Stryker Corporation
-1.74%
12.63%
29.69%
39.52%
65.3%
Boston Scientific Corp.
Boston Scientific Corp.
-3.65%
8.81%
37.74%
36.78%
49.42%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
-5.35%
11.66%
-9.57%
14.77%
72.49%
Abbott Laboratories
Abbott Laboratories
-8.13%
-7.12%
-7.24%
10.34%
61.08%
Medtronic Plc
Medtronic Plc
-6.35%
5.04%
-9.72%
-14.17%
-3.3%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Procept Biorobotics
Procept Biorobotics
53.06
NA
NA
-2.2
-0.46
-0.19
0.0
3.85
Stryker Corporation
Stryker Corporation
31.67
31.67
2.85
10.16
16.45
0.06
0.01
44.51
Boston Scientific Corp.
Boston Scientific Corp.
41.52
41.52
2.53
1.95
4.89
0.04
0.0
12.42
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
35.64
35.64
3.07
2.55
0.25
0.13
0.0
9.87
Abbott Laboratories
Abbott Laboratories
24.48
24.48
18.76
4.11
16.03
0.06
0.02
21.28
Medtronic Plc
Medtronic Plc
18.11
18.11
3.04
5.28
7.81
0.04
0.03
38.69
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Procept Biorobotics
Procept Biorobotics
Buy
$1.5B
-19.12%
53.06
-115.53%
Stryker Corporation
Stryker Corporation
Buy
$105.1B
65.3%
31.67
13.86%
Boston Scientific Corp.
Boston Scientific Corp.
Buy
$72.9B
49.42%
41.52
6.92%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
Buy
$51.0B
72.49%
35.64
27.07%
Abbott Laboratories
Abbott Laboratories
Buy
$175.3B
61.08%
24.48
13.98%
Medtronic Plc
Medtronic Plc
Buy
$110.6B
-3.3%
18.11
12.03%

Institutional Holdings

  • FMR Inc

    14.54%

  • Cpmg Inc

    11.83%

  • Vanguard Group Inc

    7.26%

  • T. Rowe Price Investment Management,Inc.

    6.05%

  • BlackRock Inc

    4.22%

  • T. Rowe Price Associates, Inc.

    2.98%

Company Information

based in silicon valley, procept biorobotics is a privately held surgical robotics company enabling better patient care by developing transformative solutions in urology. with an initial focus on benign prostatic hyperplasia (bph), the company’s first product, the aquabeam system delivering aquablation therapy, is the world’s first commercially available minimally invasive surgical robot providing autonomous tissue removal to safely and effectively treat bph. aquablation therapy offers predictable and reproducible outcomes, independent of prostate anatomy or surgeon experience.

Organization
Procept Biorobotics
Employees
428
CEO
Dr. Reza Zadno Ph.D.
Industry
Healthcare

Discover More

FAQs